FAP and neoplasm: This leads to better LNCaP tumor-to-blood contrast ratios for [68Ga]Ga-AV01084 (4.09 ± 0.77) and [68Ga]Ga-AV01088 (4.10 ± 0.88) (Table S4) than our previously reported bispecific PSMA/FAP tracers (0.48–0.89) [28].